The RNA Transcript, August 3, 2020
|
|
This fall, join our RNA Student & Postdoc Council!
|
|
The objectives of this council are to work collaboratively across disciplines, build a scientific community, and generate ideas and activities that advance RNA research and education across the University of Michigan.
This is a great opportunity to develop and implement ideas that enhance your curriculum and experience at U-M. The Council is also an excellent platform to further engage with peers, mentors, and faculty from the RNA research community.
|
|
Defending your Ph.D. thesis on an RNA-related topic?
Let us know
so we can share the great news with the RNA community!
|
|
The University of Michigan Center for RNA Biomedicine regroups over 150 faculty members and their labs across seven Schools and Colleges on the Ann Arbor campus. We're pleased to feature these outstanding scientists and colleagues in our weekly news.
|
|
Professor, Associate Division Chief for Basic Research, Hematology-Oncology Division; Section Head, Genitourinary Medical Oncology Section, Internal Medicine, Medical School
Dr. Alumkal recently joined the U-M Center for RNA Biomedicine.
Welcome to the RNA Community!
|
|
Single-Cell Transcriptome Analysis of Tumor Immune Microenvironment
|
|
Shuo Gu, Ph.D.
“A tale of tails: How 3’ uridylation alters miRNA function”
Moderator: Sandra L. Wolin, M.D., Ph.D.
|
|
Our members' publications are available through Altmetric.
Five queries are currently available: "RNA," "microRNA," "Transcriptome," "Translation," and "Molecule." Please make sure to have at least one of these key words in your title or abstract. Below are highlights from the last four weeks.
|
|
Identification of the initial nucleocapsid recognition element in the HIV-1 RNA packaging signal
Pengfei Ding, Siarhei Kharytonchyk, Alexis Waller, Ugonna Mbaekwe, SapnaBasappa, Nansen Kuo, Heather M. Frank, Christina Quasney, Aaron Kidane, Canessa Swanson, Verna Van,
Mitali Sarkar, Emily Cannistraci, RidhiChaudhary, Hana Flores, Alice Telesnitsky, Michael F. Summers.
Proceedings of the National Academy of Sciences
Jul 2020, 202008519;
Our findings suggest a sequential NC binding mechanism for Gag-genome assembly and identify a potential RNA Achilles’ heel to which HIV therapeutics may be targeted.
|
|
Postdoctoral and Staff Scientist Positions at the
Alumkal Lab
at the University of Michigan
Joshi Alumkal's lab is recruiting a post-doc and a staff scientist focused on transcriptional regulation and lineage plasticity/drug resistance in prostate cancer. The positions are intended for highly-motivated individuals with an M.D. and/or Ph.D. with expertise in cell and molecular biology, biochemistry, or epigenetics. Experience with cancer research is preferred.
|
|
Postdoctoral positions in the
Keane lab
at the University of Michigan
The Keane lab is actively seeking postdocs how have experience with RNA biochemistry or NMR spectroscopy. Candidates should email Professor Keane (
sckeane@umich.edu
) their CV and the contact information for three references.
|
|
Postdoctoral positions at
Hariadi Lab
at Arizona State University
NIH–funded positions in multi-disciplinary research, Hariadi Lab, Arizona State University
Your profile:
1. Have expertise in at least one of these areas: (i) DNA nanotechnology, (ii) super-resolution microscopy, (iii) molecular biology (e.g., cytoskeleton), (iv) cryo electron microscopy, and (v) virology.
2. Have a Ph.D. or nearing completion of a Ph.D. in Physics, Molecular & Cellular Biology, Biomedical Engineering, Biochemistry, or related topics.
3. Some computational/analytical skill would be a distinct advantage.
|
|
Volunteers for testing COVID-19 mRNA vaccine
|
|
Call for volunteers for the Moderna COVID-19
Vaccine Trial
Henry Ford Health System
is enrolling volunteers into the randomized double-blind study of whether a two-dose vaccine prevents COVID-19 infection in those exposed to the coronavirus.
A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial, which will be conducted at U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19.
|
|
|
|
SHARE YOUR NEWS AND COMMENTS
|
|
|
|
|
|
|
